DMPK

Comprehensive in vitro DMPK services are available to support drug discovery and development. These assays assess metabolic stability, protein binding, drug–drug interactions, and transporter activity across multiple species, helping to predict pharmacokinetic behavior and safety in humans.

DMPK Capabilities

  • 1. Metabolic Stability Studies

    • Evaluate compound half-life in liver microsomes, S9 fractions, and hepatocytes from human and preclinical species.

    • Measure intrinsic clearance and identify metabolic liabilities.

    2. CYP450 Inhibition & Induction Assays

    • Assess potential drug–drug interactions by testing inhibition or induction of major CYP enzymes (CYP1A2, 2C9, 2C19, 2D6, 3A4).

    3. Plasma Protein Binding (PPB)

    • Determine drug binding to plasma proteins (albumin, α1-acid glycoprotein) using equilibrium dialysis, ultrafiltration, or ultracentrifugation.

    • Provide species-specific PPB data for human, rat, dog, and non-human primates.

    4. Blood-to-Plasma Partitioning

    • Evaluate drug distribution between red blood cells and plasma to support pharmacokinetics and tissue exposure.

  • 5. Metabolite Identification & Profiling

    • Identify and characterize metabolites using LC-MS/MS and HRMS.

    • Map metabolic pathways and detect potential reactive metabolites.

    6. Drug Permeability & Transporter Studies

    • Caco-2 & MDCK permeability assays for passive/active transport.

    • Efflux transporter assays (P-gp, BCRP).

    • Uptake transporter assays (OATP, OAT, OCT).

    7. Drug Stability & Solubility

    • Assess compound solubility in PBS and simulated gastric/intestinal fluids.

    • Evaluate chemical and enzymatic stability in biological matrices (plasma, microsomes).

    8. Customized DMPK Study Designs

    • Tailored assay design to fit specific compound requirements.

    • GLP and non-GLP compliant workflows supporting IND-enabling studies.